Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS).

Full DD Report for ADMS

You must become a subscriber to view this report.


Recent News from (NASDAQ: ADMS)

JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions
Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size ...
Source: SeekingAlpha
Date: May, 14 2018 11:37
JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space
Welcome to the fourteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size...
Source: SeekingAlpha
Date: May, 07 2018 15:40
Adamas Pharmaceuticals' (ADMS) CEO Gregory Went on Q1 2018 Results - Earnings Call Transcript
Adamas Pharmaceuticals, Inc. (ADMS) Q1 2018 Results Earnings Conference Call May 3, 2018, 04:30 PM ET Executives Ashleigh Barreto - Director, Corporate Communications & IR Gregory Went - Chairman and CEO Alfred Merriweather - CFO Richard King - COO Rajiv Patni - Chief Med...
Source: SeekingAlpha
Date: May, 03 2018 21:26
Adamas Pharma beats by $0.02, beats on revenue
Adamas Pharma (NASDAQ: ADMS ): Q1 EPS of -$1.35 beats by $0.02 . More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 03 2018 16:40
Adamas Reports First Quarter 2018 Financial Results
GOCOVRI™ (amantadine) extended release capsules product sales hit $2.6 million for the first quarter of commercialization, with 1,608 fulfilled prescriptions Received positive feedback from the U.S. Food and Drug Administration (FDA) on the clinical development program for ADS-...
Source: GlobeNewswire
Date: May, 03 2018 16:05
JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond
Welcome to the thirteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size...
Source: SeekingAlpha
Date: May, 01 2018 02:41
Adamas to Announce First Quarter 2018 Financial Results and Host Conference Call on May 3, 2018
EMERYVILLE, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report first quarter 2018 financial results on Thursday, May 3, 2018, after market close. Subsequently, Adamas’ management team will host a conferen...
Source: GlobeNewswire
Date: April, 26 2018 16:05
JF's Core Biotech Buys #12: Updates And Introducing Our 18th Selection
Welcome to the twelfth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size o...
Source: SeekingAlpha
Date: April, 24 2018 01:42
3 Things In Biotech, April 22: All These 'A' Companies
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a...
Source: SeekingAlpha
Date: April, 23 2018 09:04
Blog Exposure - Adamas Pharma Announced Final Results from EASE LID 2 Study Evaluating GOCOVRI in Parkinson's Disease Patients with Dyskinesia
Stock Monitor: Galectin Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors.com has just released a free research report on Adamas Pharma, Inc. (NASDAQ: ADMS ). If you want access to this report all you need to do is sign up now by clickin...
Source: ACCESSWIRE IA
Date: April, 23 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1831.6932.6732.8530.03581,835
2018-05-1731.6932.6732.8530.03581,835
2017-02-0316.2416.3716.50316.00108,828
2017-02-0215.9216.0816.2915.68105,673
2017-02-0115.9715.9416.1815.68147,628

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-22174,039248,05970.1603Short
2018-05-21327,072389,83883.8995Short
2018-05-18128,358176,66272.6574Short
2018-05-1750,528201,66325.0557Cover
2018-05-1667,619187,12336.1361Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ADMS.


About Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS)

Logo for Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ADMS)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 03 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 03 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 26 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 26 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: April, 24 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: April, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 13 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 12 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 12 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: March, 08 2018

       

       


      Daily Technical Chart for (NASDAQ: ADMS)

      Daily Technical Chart for (NASDAQ: ADMS)


      Stay tuned for daily updates and more on (NASDAQ: ADMS)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ADMS)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      OTC Report
      @OTCReporter

       

       


      Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ADMS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of ADMS and does not buy, sell, or trade any shares of ADMS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/